

## [Desmopressin](#)

Statut de médicament essentiel

Section:

[10. Medicines affecting the blood](#) [10.2. Medicines affecting coagulation](#)

Codes ATC: [H01BA02](#)

EMLc

Indication

Von Willebrand disease Code ICD11: [3B12](#)

INN

Desmopressin

Type de médicament

Chemical agent

Type de liste

Liste de base

Formulations

**Parenteral > General injections > IV:** 4 µg per mL in 1 mL ampoule (acetate)

**Local > Nasal > Spray:** 150 µg per actuation (acetate)

Historique des statuts LME

Ajouté pour la première fois en 1991 ([TRS 825](#))

Modifié en 1993 ([TRS 850](#))

Retiré en 2003 ([TRS 920](#))

Ajouté en 2015 ([TRS 994](#))

Modifié en 2025 ([TRS 1064](#))

Sexe

Tous

Âge

Aussi recommandé pour les enfants

Équivalence thérapeutique

La recommandation concerne ce médicament spécifique

Renseignements sur le brevet

Patents have expired in most jurisdictions

Lire la suite [sur les brevets](#).

Wikipédia

[Desmopressin](#)

DrugBank

[Desmopressin](#)

Résumé des preuves et recommandation du comité d'experts



Following the review of the age-appropriateness of formulations of essential medicines for children, the Expert Committee recommended the following changes for the listing of desmopressin: - removal of desmopressin nasal spray 10 micrograms per dose - addition of desmopressin nasal spray 150 micrograms per actuation - changes to the description of the listing to correctly describe the strength of the formulations in micrograms of desmopressin acetate, and to reflect the delivered amount of nasal spray per actuation, rather than per dose (since a dose may comprise more than one actuation (spray)). Following consideration of the submission from the World Federation of Hemophilia which included a request to transfer the current listings of plasma-derived coagulation factors from the complementary to the core list, the Expert Committee recommended that the listing for desmopressin also be transferred from the complementary to the core list.